Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of LY2409021 in Healthy Subjects
NCT02217618Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adomeglivant in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Curve of LY2409021, Maximum Concentration of LY2409021 and 1 more. Started Aug 2014; status: completed.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02217618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217618.